Tuesday , May 11 2021

connection between faxes for rare faxes. Women under 50 are at risk

The drug surveillance checks on AstraZeneca are going through quickly and, compared to last week, Ema will now take a step forward. Last week, the statement was more or less as follows: “The cause-and-effect relationship between the cases of thrombosis and vaccination has not been proven.” In these hours there will be a change: further insights make Ema (the European Medicines Agency) say that the link exists, even if it is not clear what the mechanism is. Given that we continue to talk about very rare events, the risk-benefit ratio remains favorable for the use of the Covid vaccine: in Italy, an average of 400-500 people die every day from this disease and another 200-300 end up in intensive care. However, some countries – primarily Germany – have already decided to reserve AstraZeneca only for the 1960s, as there is a constant in cases of reported serious adverse reactions: they normally deal with people below the fifty years (but there are also between 50 and 60) and 80 percent are women. Even the United Kingdom (which is not dependent on Ema) confirmed three days ago that it had verified 30 cases of blood clots, but always in a very low percentage, given that a total of 18 million injections were reported.


In Germany, the Paul-Herlich Institute reports a total of 2.7 million injections “31 cases of sinus vein thrombosis after vaccination with AstraZeneca’s COVID-19 vaccine; thrombocytopenia was also reported in 19; the result was fatal in 9; with the exception of two cases, all reports concerning women ranged in age from 20 to 63 years. The two men were 36 and 57 years old “. Yesterday in Messina a 45-year-old lawyer was hospitalized in very serious circumstances, due to a thrombosis: a few weeks ago he was vaccinated with AstraZeneca. The prosecutor has opened a file, of course today can not be said that hospital admission is linked to vaccination, it remains to be understood why in Sicily there are many more reports of this type than in the rest of Italy.

AstraZeneca, a lawyer at the hospital in Messina, received the fax two weeks ago

As early as last week, EMAs PRAC (Safety Commission) had explained that it was continuing the “continuous evaluation of very rare cases of unusual blood clots associated with a low platelet count”. And it was announced: “Based on all the data currently available, the Pharmacovigilance Committee of the European Medicines Agency EMA, the Prac, should issue an updated recommendation on the AstraZeneca anti-Covid vaccine during its plenary session in April, scheduled from 6 to 9 ». Thus, scientists will meet today to decide how to make an “updated recommendation”, following an evaluation of the data and input from “independent external experts with a range of medical specialties, including hematologists, neurologists and epidemiologists.”

Covid, what summer will it be? Two scenarios, concluding with the predominant South African variant


As explained by Emer Cooke, Director of EMA, “the experts were unable to identify specific risk factors, including age, gender or a history of coagulation disorders, for these very rare events”. But as a conclusion of Ema, indeed of this committee called Prac (Pharmacovigilance Risk Assessment Committee), had been cautious a week ago (“a causal link with the AstraZeneca anti-Covid vaccine, for cases of rare thrombosis reported after administration, it has not been proven “), in the next few hours the update of the recommendations will continue and clarify that there is a relationship cause effect. Although these cases are rare, it will be necessary to understand whether they are due to the AstraZeneca product or to the type of viral vector vaccines (Pfizer and Moderna are not, Johnson & Johnson yes).

AstraZeneca, risks for young people increase? Ferguson: “Small contraindications for parents”

Source link